Sanofi and Regeneron present more positive data for Dupixent product

sanofi-and-regeneron-present-more-positive-data-for-dupixent-product
2/2

Sanofi and Regeneron present more positive data for Dupixent product © Reuters. FILE PHOTO: A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier

2/2

PARIS (Reuters) – Healthcare companies Sanofi (NASDAQ:) and partner Regeneron (NASDAQ:) presented on Tuesday more positive data for their Dupixent product.

The companies said new data showed that Dupixent showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.

Related Articles

Responses

Your email address will not be published. Required fields are marked *